Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial (Q37218730)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 January 2012

Language	Label	Description	Also known as
English	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial	scientific article published on 26 January 2012

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial (English)

1 reference

Europe PubMed Central

19 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Philip W. Kantoff

12

object named as

Philip W Kantoff

1 reference

Europe PubMed Central

19 August 2017

Mary-Ellen Taplin

13

object named as

Mary E Taplin

1 reference

Europe PubMed Central

19 August 2017

5

object named as

Jerome P Richie

1 reference

Europe PubMed Central

19 August 2017

Toni K Choueiri

10

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

19 August 2017

author name string

Robert W Ross

1

1 reference

Europe PubMed Central

19 August 2017

Matthew D Galsky

2

1 reference

Europe PubMed Central

19 August 2017

Phil Febbo

3

1 reference

Europe PubMed Central

19 August 2017

Marc Barry

4

1 reference

Europe PubMed Central

19 August 2017

Wanling Xie

6

1 reference

Europe PubMed Central

19 August 2017

Fiona M Fennessy

7

1 reference

Europe PubMed Central

19 August 2017

Rupal S Bhatt

8

1 reference

Europe PubMed Central

19 August 2017

Julia Hayes

9

1 reference

Europe PubMed Central

19 August 2017

Clare M Tempany

11

1 reference

Europe PubMed Central

19 August 2017

William K Oh

14

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

26 January 2012

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

118

1 reference

Europe PubMed Central

19 August 2017

19

1 reference

Europe PubMed Central

19 August 2017

4777-4784

1 reference

Europe PubMed Central

19 August 2017

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Reversal of docetaxel resistance with bevacizumab and thalidomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

6 September 2017

Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

14 September 2017

Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

14 September 2017

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

3 September 2018

Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

3 September 2018

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

3 September 2018

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

3 September 2018

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791849

3 September 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27416

21 January 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27416

21 January 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27416

21 January 2018

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27416

21 January 2018

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormonal treatment before radical prostatectomy: a 3-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22282219

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.27416

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37218730&oldid=1694873510"